| 3.87 0.08 (2.11%) | 04-30 12:53 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.03 |
1-year : | 5.87 |
| Resists | First : | 4.3 |
Second : | 5.03 |
| Pivot price | 4.01 |
|||
| Supports | First : | 3.78 |
Second : | 3.46 |
| MAs | MA(5) : | 3.85  |
MA(20) : | 3.96 |
| MA(100) : | 4.27 |
MA(250) : | 5.83 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 13.3 |
D(3) : | 19 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 11.67 | Low : | 3.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NTRB ] has closed above bottom band by 30.3%. Bollinger Bands are 21.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.88 - 3.92 | 3.92 - 3.94 |
| Low: | 3.64 - 3.69 | 3.69 - 3.72 |
| Close: | 3.67 - 3.74 | 3.74 - 3.79 |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Wed, 29 Apr 2026
[10-K] NutriBand Inc. Files Annual Report - Stock Titan
Wed, 29 Apr 2026
NutriBand 10-K: Revenue $2.04M, EPS (2.58) for year ended Jan 31, 2026 - TradingView
Wed, 22 Apr 2026
Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 4.91e+006 (%) |
| Held by Institutions | 74.3 (%) |
| Shares Short | 203 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.03e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 121.3 % |
| Return on Equity (ttm) | -55.3 % |
| Qtrly Rev. Growth | 2.28e+006 % |
| Gross Profit (p.s.) | -24.05 |
| Sales Per Share | -70.51 |
| EBITDA (p.s.) | 395497 |
| Qtrly Earnings Growth | -3.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 12.1 |
| Dividend | 0 |
| Forward Dividend | 217560 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|